Frontier Medicines progresses deal with AbbVie

US precision medicines firm Frontier Medicines today announced the second and third programs under the company's global partnership with AbbVie (NYSE: ABBV) have advanced into lead generation. These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier Platform.

"Our collaboration with Frontier is continuing to make progress against difficult-to-drug protein targets," said Jonathon Sedgwick, vice president and global head, discovery research, at AbbVie. "Two years into our partnership, Frontier's technology is showing important advances in the drugging of previously inaccessible biology, this time towards enabling binders for novel E3 ligases, with the potential to be applied to the discovery and development of new and better therapeutic options for patients," he noted.

Chris Varma, Frontier's co-founder, chairman, and chief executive, commented: "Our delivery of three programs into lead generation further validates The Frontier Platform's ability to systematically discover and deliver small molecules to drug undruggable targets. We look forward to progressing these novel breakthrough discoveries to help advance transformative care for patients."